SEBI-encouraged funds — venture capital, SME, social-impact and infrastructure. Close-ended, generally unleveraged.
IXP Lifesciences Catalyst Fund is an early-stage venture capital platform focused on supporting Lifesciences startups from pre-seed to Series A. Built by industry veterans, the fund combines capital with ecosystem support, venture studio capabilities, and deep domain expertise to help scientists and innovators translate research into scalable businesses across biopharma, medical technology, nutraceuticals, cosmeceuticals, and specialty chemicals.
Ketki Tulpule
Chief Innovation Officer
Ph.D.
Ketki is a techno-commercial professional with a deep understanding of the Lifesciences value chain and 15 years of experience in industry as well as academia. She completed her M.Sc. in Biochemistry and Ph.D. in Neurochemistry from University of Bremen, Germany followed by a Postdoc in Neurobiology from IISER Pune. She brings diverse experience including AI/ML-based drug discovery and development solutions, Lifesciences infrastructure and cluster building, business development and strategy. Her past affiliations include Rx Propellant, Excelra and Aragen (erstwhile GVK Bio) and Max Plank Institute for Marine Microbiology.
Vishal Goel
Partner
Co-founder of JV Ventures with 20+ years in Lifesciences, consulting, and infrastructure development. Harvard alumnus with experience across EY, Alexandria Real Estate India, and Red Fort Capital.
Jasmeet Chhabra
Partner
Co-founder of JV Ventures with 20+ years of experience in investment and fundraising. Led capital raising across multiple funds totaling USD 600M+ with deep expertise in investor relations and scaling platforms.
Manoj Nerurkar
Advisor
Ph.D.
Manoj has 25+ years of experience in pharmaceutical development from Phase I to the commercialization stage. He served as the COO of Syngene International Ltd., and also held key technical and management roles at leading organizations such as Bristol Myers Squibb and Novartis, driving advancements in pharmaceutical innovation. He holds a Ph.D. in Pharmaceutical Chemistry from the University of Kansas and has completed a management program at The Wharton School of Business. Manoj is the founding member of an innovative drug delivery start-up which has forged partnerships with leading companies globally.
No insights published yet.
Investments in AIFs carry market and credit risk including possible loss of capital. Past performance does not indicate future returns. Information shown is sourced from the issuer's PPM and SEBI filings — confirm against the latest PPM before committing. Wisefolio is an information platform; it is not registered with SEBI as an investment adviser, portfolio manager, or distributor. By using this page you accept our terms and privacy policy, including the self-attestation that you are eligible to view AIF marketing material under SEBI rules.
Nandu Gattu
Advisor
Ph.D.
Nandu has 25+ years of experience in bioinformatics, pharmacology, and medicine across the USA, UK, and India. He has developed solutions like drug repurposing platforms genomics tools, AI/ML-based prediction models, and biomarker discovery. During his decade-long stint at GSK and Excelra, he held key roles that advanced pharmaceutical research. He brings in expertise in all aspects of drug discovery and development, including clinical sciences, pre-clinical, and computational biology. He holds a Ph.D. in Neuropharmacology from the Medical College of Georgia and completed postdoctoral research in Bioinformatics and Behavioural pharmacology.
Nirav Desai
Advisor
Ph.D.
Nirav has 25+ years of experience in biologics, vaccines, and advanced biotechnology platforms. He has co-authored over 10 peer-reviewed publications and holds 8 patents across multiple geographies. He held the senior leadership position as the Head of Vaccine and research at Cadila Pharmaceuticals. He holds a BSc in Microbiology and Biotechnology from the University of Mumbai and a Ph.D. from Gujarat University, Ahmedabad. He brings expertise in process development and yield optimization for biotechnology-based products. He is currently serving as the Founder and COO of a Hyderabad-based CDMO.
Atin Tomar
Advisor
Atin has over 20 years of experience in the Biotechnology industry, with leadership roles spanning the entire lifecycle of biologics and vaccines. He served as the President and CEO of CPL Biologics a joint venture between Cadila Pharmaceuticals Limited and Novavax Inc., USA. He holds a B.Tech (Hons) in Biotechnology and Biochemical Engineering from IIT Kharagpur, an MS in Biological Engineering from the University of Georgia, US and an MBA from ISB, Hyderabad. He brings expertise in understanding the development of Biologics/Bio-therapeutics, from the early stages of development to commercial manufacturing. He is currently serving as the Founder and CEO of a prominent CDMO based in Hyderabad.
See every PMS strategy and AIF from IXP Lifesciences.